Market closed
Acrivon Therapeutics, Inc./$ACRV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Ticker
$ACRV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
77
ISIN
US0048901096
Website
ACRV Metrics
BasicAdvanced
$37M
-
-$2.38
1.78
-
Price and volume
Market cap
$37M
Beta
1.78
52-week high
$5.75
52-week low
$1.16
Average daily volume
984K
Financial strength
Current ratio
10.551
Quick ratio
10.426
Long term debt to equity
1.464
Total debt to equity
2.062
Management effectiveness
Return on assets (TTM)
-33.30%
Return on equity (TTM)
-54.07%
Valuation
Price to book
0.21
Price to tangible book (TTM)
0.21
Price to free cash flow (TTM)
-0.583
Growth
Earnings per share change (TTM)
-12.84%
3-year earnings per share growth (CAGR)
-36.52%
ACRV News
AllArticlesVideos
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
GlobeNewsWire·2 weeks ago
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
GlobeNewsWire·1 month ago
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Acrivon Therapeutics, Inc. stock?
Acrivon Therapeutics, Inc. (ACRV) has a market cap of $37M as of May 10, 2025.
What is the P/E ratio for Acrivon Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Acrivon Therapeutics, Inc. (ACRV) stock is 0 as of May 10, 2025.
Does Acrivon Therapeutics, Inc. stock pay dividends?
No, Acrivon Therapeutics, Inc. (ACRV) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Acrivon Therapeutics, Inc. dividend payment date?
Acrivon Therapeutics, Inc. (ACRV) stock does not pay dividends to its shareholders.
What is the beta indicator for Acrivon Therapeutics, Inc.?
Acrivon Therapeutics, Inc. (ACRV) has a beta rating of 1.78. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.